Patents Assigned to Milestone Pharmaceuticals
  • Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof
    Patent number: 10117848
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: November 6, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventor: Martin P. Maguire
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 10010522
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 10010524
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 10010523
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 9737503
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: August 22, 2017
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 9463179
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting phenylalkylamine calcium channel blockers and uses thereof
    Patent number: 9227918
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 5, 2016
    Assignee: Milestone Pharmaceuticals
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Short acting benzothiazepine calcium channel blockers and uses thereof
    Patent number: 8501727
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 6, 2013
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton
  • SHORT ACTING BENZOTHIAZEPINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF
    Publication number: 20110144087
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 16, 2011
    Applicant: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton
  • SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF
    Publication number: 20100190852
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: June 19, 2008
    Publication date: July 29, 2010
    Applicant: MILESTONE PHARMACEUTICALS INC.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton